复宏汉霖(02696.HK)：HLX43用于治疗晚期非小细胞肺癌(NSCLC)的国际多中心2期临床研究完成美国首例患者给药

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in the United States for its international multicenter Phase II clinical study of HLX43, a PD-L1 targeted antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1 - The Phase II clinical study is also being conducted simultaneously in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The company plans to conduct clinical trials in Australia and Japan once conditions are met [1]